ABSTRACT
Background/Aim: High-grade gliomas are aggressive brain neoplasms usually refractory to treatment. Recently new treatment approaches have emerged, including immunotherapies. Hence, the aim of the present study was to evaluate the efficacy and safety of immunotherapies in adult patients with high-grade gliomas. Methods: Searches were performed in three databases for relevant studies published until December 2020. Title and abstract screening, full-text review, data extraction, and risk of bias assessment were performed independently by two reviewers. Risk of bias assessment was performed according to the revised Cochrane risk-of-bias tool for randomized trials (RoB 2). Meta-analyses were performed with Review Manager software (version 5.4.1), using risk ratio and 95% confidence intervals as measure of effect, the Mantel-Haenszel method, and random effects models. The quality of evidence assessment was conducted according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: Nineteen studies were included in the systematic review, of which 15 reported comparable data for meta-analyses. The outcomes assessed in the meta-analyses were overall survival (OS) and progression-free survival (PFS), with subgroups at 6, 12, and more than 12 months. No statistical differences were observed between immunotherapy and conventional treatment, except for the OS subgroup over 12 months. The certainty on the evidence was moderate. Conclusion: There was no evidence of an additional benefit of immunotherapy compared to standard treatment in the synthesis of results from clinical trials. Further high-quality clinical trials are needed to improve the quality of evidence concerning immunotherapies for the treatment of high-grade gliomas.
ABSTRACT
Introducción: Nimotuzumab es una inmunoglobina de isotipo IgG1, obtenido por tecnología de ADN recombinante. La expectativa de vida de niños con tumores cerebrales recurrentes, refractarios a tratamientos a la cirugía, la radioterapia y la quimioterapia es de un mes aproximadamente. Con este tratamiento la supervivencia alcanza 44,5 meses. Objetivos: Presentar el caso clínico de un paciente con diagnóstico de Astrocitoma anaplásico que recibió tratamiento oncoespecífico concurrente con Nimotuzumab. Presentación de caso: Se realizó la descripción del diagnóstico, tratamiento y evolución de un paciente de 31 años de edad que fue diagnosticado con una neoplasia del sistema nervioso central. (Astrocitoma anaplásico). Recibió la combinación terapéutica de cirugía, radioterapia y anticuerpos monoclonales, lográndose una sobrevida de 39 meses. Conclusiones: La adición del anticuerpo monoclonal al tratamiento estándar de los tumores cerebrales aumentó la sobrevida del paciente, convirtiéndose en una alternativa terapéutica segura, ventajosa y factible como parte del tratamiento convencional en las condiciones asistenciales(AU)
Introduction: Nimotuzumab is an IgG1 isotype immunoglobin, obtained by recombinant DNA technology. Life expectancy is approximately one month in children with recurrent brain tumors, refractory to treatments to surgery, radiotherapy and chemotherapy. Survival reaches 44.5 months when using Nimotuzumab. Objectives: To report the clinical case of a patient diagnosed with anaplastic astrocytoma who received concurrent oncospecific treatment with Nimotuzumab. Case report: This paper describes the diagnosis, treatment and evolution of a 31-year-old male patient with neoplasm of the central nervous system (Anaplastic astrocytoma). He received the therapeutic combination of surgery, radiotherapy and monoclonal antibodies, achieving a survival of 39 months. Conclusions: The adding the monoclonal antibody to the standard treatment of brain tumors increased patient survival, making it a safe, advantageous and feasible therapeutic alternative as part of conventional treatment in healthcare conditions(AU)
Subject(s)
Humans , Male , Adult , Astrocytoma/surgery , Astrocytoma/diagnosis , Astrocytoma/therapy , Central Nervous System , Reference Drugs , Antibodies, Monoclonal, Humanized/therapeutic use , Survival AnalysisABSTRACT
RESUMEN Introducción: el astrocitoma anaplásico y el glioblastoma multiforme son las formas más agresivas de glioma maligno. Existen avances en radioterapia, quimioterapia y tratamientos de resección quirúrgica agresiva. Esto último incluye métodos como los de tomografía de coherencia óptica, cirugía guiada por fluorescencia, craneotomía de vigilia, terapia térmica intersticial con láser para la ablación por glioblastoma multiforme, microscopía intraoperatoria confocal y espectrometría de masas intraoperatoria, pero a pesar de todo ello el pronóstico resulta sombrío. Objetivo: determinar el comportamiento de los gliomas de alto grado en el Servicio de Neurocirugía de la provincia Matanzas. Materiales y métodos: estudio observacional, descriptivo, transversal, con los pacientes diagnosticados de gliomas de alto grado, en el Servicio Neurocirugía, de la provincia Matanzas, en el período de 1ero de enero del 2017 a 1ero de enero del 2019, para un total de 40 casos. Resultados: la edad media de las lesiones fue de 52 años, la cefalea fue el síntoma predominante, con el 72,2 %. La sintomatología se presentó con una evolución de menos de un mes. Conclusiones: en el 62 % predominaron los gliomas frontales y la variedad histológica glioblastoma multiforme. La excéresis subtotal se aplicó en la mayor cantidad de cirugías, la calidad de vida al egreso fue superior que al ingreso (AU).
ABSTRACT Introduction. Anaplastic astrocytoma (AA) and Glioblastoma multiforme (GBM) are the most aggressive forms of malignant glioma. Despite advances in radiotherapy, chemotherapy and aggressive surgical resection treatments, such as optical coherence tomography, fluorescence-guided surgery, waking craniotomy, laser interstitial thermal therapy for GBM ablation, intraoperative confocal microscopy and intraoperative mass spectrometry, the prognosis remains bleak. Objective: to determine the behavior of high grade gliomas in the Neurosurgery Service of the province of Matanzas. Materials and methods: cross-sectional, descriptive, observational study with patients diagnosed with high-grade gliomas in the Neurosurgery Service of the province of Matanzas, in the period from January 1, 2017 to January 1, 2019, for a total of 40 cases. Results: the average age of the lesionated patients was 52 years; headache was the predominant symptom, with 72.2 %; the evolution at the presentation of symptoms was less than a month. Conclusions: frontal gliomas predominated in 62 % of the cases, and predominated also glioblastoma multiforme histological variety. Subtotal excision was used in most surgeries. Life quality at discharging was higher than at the moment of admission (AU).
Subject(s)
Humans , Glioma/epidemiology , Epidemiology, Descriptive , Cross-Sectional Studies , Observational Study , Glioma/surgery , Glioma/diagnosis , NeurosurgeryABSTRACT
Objective To analyze the efficacy and prognostic factors of postoperative radiotherapy for high grade gliomas based on MRI guided target delineation. Methods Retrospective analysis was conducted on 111 patients with high-grade gliomas from October 2010 to December 2015. The patients were treated with IMRT in combination with temozolomide guided by MRI-CT fusion technique after target delineation at preoperation, postoperation ( < 72 h ) and before radiotherapy. The survival rate was calculated by K-M method. The analyses of single factor and multiple factor, ranging from the patients′age, gender, pathological grade, number of lesions, multiple lobes, tumour crossing the midline,epilepsy, the maximum diameter of the lesions, adjuvant chemotherapy and other factors on prognosis were conducted with Log-Rank test and COX regression analysis. Results A total of 111 patients met the criteria for admission, and the overall follow-up rate was 94. 6%. The survival rates of 1-, 2-, 3-, 4-, 5- year were 81. 6%, 54. 2%, 39. 1%, 25. 4%, 15. 5%, respectively. The median survival time was 38 months. The single factor analysis showed that pathological grading (χ2 =5. 549, P<0. 05), age (χ2 =6. 393, P<0. 05), preoperative tumor maximum diameter (χ2 =4. 555, P<0. 05) and adjuvant chemotherapy (χ2 =4. 965, P <0. 05 ) were correlated with on the survival rate, while multivariate analysis showed that pathological grade Ⅲ, younger age, preoperative tumor with size smaller contributed to the good prognosis (Wald=4. 784, 4. 560, 5. 859, P<0. 05). Conclusions High grade gliomas after operation by MRI-CT fusion technique in preoperative and postoperative 72 h and MRI before radiotherapy guided by radiotherapy, for intensity-modulated radiotherapy combined with temozolomide chemotherapy, can obtain better efficacy. The grade Ⅲ of glioma, <50 years old, the maximum diameter of the tumor <6 cm, the adjuvant chemotherapy may have the better prognosis.
ABSTRACT
Objective To analyze the efficacy and prognostic factors of postoperative radiotherapy for high grade gliomas based on MRI guided target delineation. Methods Retrospective analysis was conducted on 111 patients with high-grade gliomas from October 2010 to December 2015. The patients were treated with IMRT in combination with temozolomide guided by MRI-CT fusion technique after target delineation at preoperation, postoperation ( < 72 h ) and before radiotherapy. The survival rate was calculated by K-M method. The analyses of single factor and multiple factor, ranging from the patients′age, gender, pathological grade, number of lesions, multiple lobes, tumour crossing the midline,epilepsy, the maximum diameter of the lesions, adjuvant chemotherapy and other factors on prognosis were conducted with Log-Rank test and COX regression analysis. Results A total of 111 patients met the criteria for admission, and the overall follow-up rate was 94. 6%. The survival rates of 1-, 2-, 3-, 4-, 5- year were 81. 6%, 54. 2%, 39. 1%, 25. 4%, 15. 5%, respectively. The median survival time was 38 months. The single factor analysis showed that pathological grading (χ2 =5. 549, P<0. 05), age (χ2 =6. 393, P<0. 05), preoperative tumor maximum diameter (χ2 =4. 555, P<0. 05) and adjuvant chemotherapy (χ2 =4. 965, P <0. 05 ) were correlated with on the survival rate, while multivariate analysis showed that pathological grade Ⅲ, younger age, preoperative tumor with size smaller contributed to the good prognosis (Wald=4. 784, 4. 560, 5. 859, P<0. 05). Conclusions High grade gliomas after operation by MRI-CT fusion technique in preoperative and postoperative 72 h and MRI before radiotherapy guided by radiotherapy, for intensity-modulated radiotherapy combined with temozolomide chemotherapy, can obtain better efficacy. The grade Ⅲ of glioma, <50 years old, the maximum diameter of the tumor <6 cm, the adjuvant chemotherapy may have the better prognosis.
ABSTRACT
OBJECTIVE: The relationship between brain tumors and cognitive deficits is well established in the literature. However, studies investigating the cognitive status in low and high-grade gliomas patients are scarce, particularly in patients with average or lower educational level. This study aimed at investigating the cognitive functioning in a sample of patients with low and high-grade gliomas before surgical intervention. METHOD: The low-grade (G1, n=19) and high-grade glioma (G2, n=8) patients underwent a detailed neuropsychological assessment of memory, executive functions, visuo-perceptive and visuo-spatial abilities, intellectual level and language. RESULTS: There was a significant impairment on verbal and visual episodic memory, executive functions including mental flexibility, nominal and categorical verbal fluency and speed of information processing in G2. G1 showed only specific deficits on verbal and visual memory recall, mental flexibility and processing speed. CONCLUSION: These findings demonstrated different levels of impairments in the executive and memory domains in patients with low and high grade gliomas.
OBJETIVO: A associação entre tumores cerebrais e déficits cognitivos é bem estabelecida na literatura. No entanto, estudos sobre a cognição de pacientes com gliomas de baixo e alto grau são escassos, especialmente, em sujeitos com baixa escolaridade. Este estudo investigou o funcionamento cognitivo de uma amostra de pacientes com gliomas de baixo e alto grau antes da intervenção cirúrgica. MÉTODO: Os pacientes com glioma de baixo grau (G1, n=19) e alto grau (G2, n=8) foram avaliados quanto à memória, funções executivas, habilidades visuo-perceptivas e visuo-espaciais, nível intelectual e linguagem. RESULTADOS: Houve prejuízo significativo em G2 na memória episódica verbal e visual, funções executivas incluindo flexibilidade mental, fluência verbal nominal e categórica e velocidade de processamento de informações. G1 demonstrou apenas déficits específicos de evocação verbal e visual, flexibilidade mental e velocidade de processamento. CONCLUSÃO: Estes achados demonstraram níveis diferenciados de comprometimento nos domínios executivos e mnésticos de pacientes com gliomas de baixo e alto grau.
Subject(s)
Adult , Humans , Middle Aged , Brain Neoplasms/complications , Cognition Disorders/etiology , Glioma/complications , Brain Neoplasms/pathology , Educational Status , Glioma/pathology , Neoplasm Staging , Neuropsychological TestsABSTRACT
High-grade gliomas are relatively frequent in adults and consist in the most malignant form of primary brain tumor. They are resistant to standard treatment modalities such as surgery, radiation, and chemotherapy, being fatal within 1 to 2 years of onset of symptoms. Owing to the promising practical clinical benefits that can be expected for the near future, an exposition of the basic issues in genetic therapy of gliomas seems timely. In this article we intend to provide a general review that covers the most important genes already studied as possible agents for genetic therapy in gliomas. In a critical analysis we intend to expose and discuss anti-tumoral mechanisms and therapeutical results of studies with the following class of genes: prodrug activation systems, apoptosis-related genes, anti-angiogenic factors genes, radiosensitization genes, chemosensitization genes, apoptosis-related genes and immunogenes. Finally we discuss the historical importance, actual role and further developments that can be expected from each of these class of agents for the future of genetic therapy of gliomas.
ABSTRACT
Background and purpose:The prognosis of high grade gliomas remains poor, and multidisciplinary treatment strategy has been much investigated recently. This study was to explore the efficacy of Temozolomide as first-line treatment combined with radiotherapy and followed by adjuvant chemotherapy for the treatment of newly diagnosed high grade gliomas. Methods:18 patients who had been pathologically proven to be high grade gliomas were enrolled into the study. The patients received 40 Gy/20fractions for the whole brain and followed by 20Gy/10fractions as a boost to tumor bed. All of the patients were given daily oral temozolomide 75mg/ m2 during radiotherapy. 4 weeks after radiotherapy, all of the patients received 6 cycles of Temozolomide, each cycle lasted 5 days with 28 days interval between each cycles. 150 mg/m2 of temozolomide was given for the first cycle for five days,followd by 200 mg/m2 of drug for the rest of the cycles if no significant drug related toxicities were observed. Results:Median follow-up was 12.5 months, 11 cases had either recurrence or progression, 5 of them died from the disease. The median time for disease progression-free survival was 9.8 months (95% CI, 6.1~9.8months), the median time for overall survival was 14 months (95% CI, 8.5 ~ 19.5months), 1-year overall survival rate was 55.6% ,6-month progression-free survival rate was 81.8%. there were no severe temozolomide related toxicities. Conclusion: Concurrent temozolomide with radiotherapy and followed by 6 cycles of temozolomide in the treatment of high grade gliomas had better clinical efficacy, the patients tolerated the strategy well and no severe toxicities were observed.